GEMP Gemphire Therapeutics Inc.

1.27
-0.03  -2%
Previous Close 1.3
Open 1.28
Price To Book 2.31
Market Cap 18117072
Shares 14,265,411
Volume 19,056
Short Ratio
Av. Daily Volume 67,472

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial terminated - noted August 10, 2018.
Gemcabene
Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
Phase 2b primary endpoint met - June 28, 2018.
Gemcabene - INDIGO-1
Severe Hypertriglyceridemia (SHTG)
Phase 2b data released August 7, 2017 - primary endpoint met but lower than expectations.
Gemcabene - ROYAL-1
Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 2b data released June 28, 2017 - primary endpoint met.
Gemcabene - COBALT-1
Homozygous Familial Hypercholesterolemia (HoFH)
Phase 2 top-line data due 2Q 2019.
Gemcabene
Familial Partial Lipodystrophy (FPL)